Kevin Gorman, Neurocrine CEO
November 22, 2021 09:27 AM EST
Deals
R&D

Bounc­ing back from a PhII flop in schiz­o­phre­nia, Neu­ro­crine steers in­to the busy M4/M1 path­way with a $100M cash deal

John Carroll

Editor & Founder

Eight months af­ter Neu­ro­crine $NBIX chron­i­cled a flop for a mid-stage schiz­o­phre­nia drug, the biotech is head­ed right back in­to Phase II armed with a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

A service from the Financial Times